Pfizer Files Supplemental Proxy Materials for 2025

TL;DR

Pfizer dropped more proxy docs for 2025 shareholder talks, no fee needed.

AI Summary

Pfizer Inc. filed a Definitive Additional Materials proxy statement on April 7, 2025, related to its 2025 shareholder engagement. This filing is supplemental to its primary proxy statement and indicates no fee was required for this submission.

Why It Matters

This filing provides additional information to shareholders regarding Pfizer's 2025 proxy season, impacting how shareholders vote on company matters.

Risk Assessment

Risk Level: low — This is a routine supplemental proxy filing with no immediate financial implications or significant new disclosures.

Key Players & Entities

• Pfizer Inc. (company) — Registrant
• 0000078003-25-000083.txt (document) — Accession Number
• 20250407 (date) — Filing Date

FAQ

From the Filing

0000078003-25-000083.txt : 20250407 0000078003-25-000083.hdr.sgml : 20250407 20250407165639 ACCESSION NUMBER: 0000078003-25-000083 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 19 FILED AS OF DATE: 20250407 DATE AS OF CHANGE: 20250407 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 25818834 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 DEFA14A 1 supplemental040725.htm DEFA14A Supplemental 04.07.25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.14a-12 Pfizer Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of filing fee (Check all boxes that apply): x No fee required ¨ Fee paid previously with preliminary materials ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Pfizer 2025 Supplemental Proxy Material April 7, 2025 Pfizer 2025 2 • Our discussions during this shareholder engagement meeting will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We include forward-looking statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; changes to Pfizer's R&D and commercial organizations; reorganizations; business plans, strategy, goals and prospects; expectations regarding Pfizer’s Board of Directors; expectations regarding modifications to certain long-term incentive awards for certain colleagues; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics, including demand, market size and utilization rates and growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; an enterprise-wide cost realignment program (including anticipated costs, savings and potential benefits); a manufacturing optimization program to reduce our cost of goods sold (including anticipated costs, savings and potential benefits); dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, including our December 2023 acquisition of Seagen, and our ability to successfully capitalize on growth opportunities and prospects; manufacturing and product supply; our Environmental, Social and Governance (ESG) priorities, strategy and goals; our ongoing efforts to respond to COVID-19; our expectations regarding the impact of COVID-19 on our business, operations and financial results; and other statements about our business, operations and financial results. Among